Form D · Biotechnology

NextPoint Therapeutics, Inc.

Cambridge, MA · CIK 0001959209

Offering snapshot reported Jul 30, 2026 · SEC filing

Reported sold
$33.7M
Offering amount: $48.7M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 22, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 30, 2026Initial$33,728,772No comparison15SEC filing
Feb 14, 2024Initial$42,479,388No comparison15SEC filing
Dec 27, 2022Initial$79,999,992No comparison13SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-592689

Source: Form D, filed Jul 30, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Detlev Biniszkiewicz Director
Ivan Cheung Director, Executive
Paul Conrad Executive
Rakhshita Dhar Director
Ansbert Gadicke Director
Paulina Hill Director
Axel Hoos Director
Jeffrey Lacey Executive
Matthew Roden Director
Matthew Roden) Director
Brian Shuster Director
R. Jacob Vogelstein Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
238 Main Street
Cambridge, MA, 02142
Phone: 508-204-1115